Department of Life Sciences, School of Science, University of Management and Technology, Lahore, Pakistan.
Riphah College of Rehabiliation and Allied Health Sciences, Riphah International University, Lahore, Pakistan.
J Med Virol. 2020 Dec;92(12):3868-3870. doi: 10.1002/jmv.25931. Epub 2020 May 17.
The recent development of direct-acting antiviral (DAA) drugs has revolutionized the area of hepatitis C virus (HCV) therapeutics but the efficacy and clinical outcome of interferon (IFN)-free therapy have not been extensively studied yet. We observed a dramatic increase in hypothyroidism among patients treated with sofosbuvir, IFN, and ribavirin. This is the first prospective study of the thyroid dysfunction in DAA drugs treated patients. This study compared the risk of hypothyroidism in two different groups of HCV patients treated with different DAA drugs regimens that were sofosbuvir + pegylated-IFN-α + ribavirin and sofosbuvir + daclatasvir + ribavirin. Our findings highlight the periodic screening of serum thyroid-stimulating hormone and T4 levels in HCV infected patients during the treatment and posttreatment.
直接作用抗病毒（DAA）药物的最新发展彻底改变了丙型肝炎病毒（HCV）治疗领域，但干扰素（IFN）免费治疗的疗效和临床结果尚未得到广泛研究。我们观察到接受索非布韦、IFN 和利巴韦林治疗的患者中甲状腺功能减退症显著增加。这是第一项关于 DAA 药物治疗患者甲状腺功能障碍的前瞻性研究。本研究比较了两种不同 DAA 药物方案治疗的 HCV 患者的甲状腺功能减退症风险，方案分别为索非布韦+聚乙二醇干扰素-α+利巴韦林和索非布韦+达卡他韦+利巴韦林。我们的研究结果强调了在 HCV 感染患者治疗和治疗后期间定期筛查血清促甲状腺激素和 T4 水平。
